PT  - JOURNAL ARTICLE
AU  - Samanovic, Marie I.
AU  - Cornelius, Amber R.
AU  - Wilson, Jimmy P.
AU  - Karmacharya, Trishala
AU  - Gray-Gaillard, Sophie L.
AU  - Allen, Joseph Richard
AU  - Hyman, Sara Wesley
AU  - Moritz, Gali
AU  - Ali, Mahnoor
AU  - Koralov, Sergei B.
AU  - Mulligan, Mark J.
AU  - Herati, Ramin Sedaghat
TI  - Poor antigen-specific responses to the second BNT162b2 mRNA vaccine dose in SARS-CoV-2-experienced individuals
AID  - 10.1101/2021.02.07.21251311
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.07.21251311
4099  - http://medrxiv.org/content/early/2021/02/09/2021.02.07.21251311.short
4100  - http://medrxiv.org/content/early/2021/02/09/2021.02.07.21251311.full
AB  - The advent of COVID-19 vaccines will play a major role in helping to end the pandemic that has killed millions worldwide. Vaccine candidates have demonstrated robust humoral responses and have protected against infection. However, efficacy trials were focused on individuals with no prior exposure to SARS-CoV-2, and, as a result, little is known about immune responses induced by these mRNA vaccines in individuals who recovered from COVID-19. Here, we evaluated immune responses in 32 subjects who received two-dose BNT162b2 mRNA vaccination. In individuals naive to SARS-CoV-2, we observed robust increases in humoral and antigen-specific antibody-secreting cell (ASC) responses following each dose of vaccine, whereas individuals with prior exposure to SARS-CoV-2 demonstrated strong humoral and antigen-specific ASC responses to the first dose but muted responses to the second dose of the vaccine for the time points studied. These data highlight an important gap in our knowledge and may have major implications for how these vaccines should be used to prevent COVID-19.One sentence summary Immune responses to the booster dose of mRNA vaccine BNT162b2 are poor in subjects with a prior history of SARS-CoV-2 infection.Competing Interest StatementMJM reported potential competing interests: laboratory research and clinical trials contracts with Lilly, Pfizer (exclusive of the current work), and Sanofi for vaccines or MAB vs SARS-CoV-2; contract funding from USG/HHS/BARDA for research specimen characterization and repository; research grant funding from USG/HHS/NIH for SARS-CoV-2 vaccine and MAB clinical trials; personal fees from Meissa Vaccines, Inc. for Scientific Advisory Board service.Funding StatementThis work was supported by NIH grants AI114852 and AI082630 (R.S.H), and AI148574 (M.J.M.).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study was performed with approval from the NYU Institutional Review Board (IRB 20-00595 and IRB 18-02037).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from this study is available upon request.